226 withdrawn. 226 Phase 1, 87 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 226 | Withdrawn 226 |
| Phase 2 | 87 | Withdrawn 87 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A | Phase 1 / Phase 2 | Withdrawn | Nationwide Children's Hospital | 2027-04-01 | 2026-07-29 | |
| Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Dexamethasone, Hyaluronic acid, Indocyanine green(ICG) - Hearing Loss, Sensorineural, Hearing Loss, Sudden | Phase 1 / Phase 2 | Withdrawn | Seoul National University Hospital | 2026-12-15 | 2026-05-22 | |
| Terazosin And Metabolic Engagement in Parkinson's Disease Terazosin Hydrochloride, Placebo - Parkinson's Disease | Phase 1 / Phase 2 | Withdrawn | Nandakumar Narayanan | 2026-09-01 | 2026-10-07 | |
| Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy SV-BR-1-GM Vaccine, Cyclophosphamide, Pembrolizumab - Brain Metastases, Leptomeningeal Metastasis | Phase 1 | Withdrawn | Medical College of Wisconsin | 2026-06-15 | 2026-06-17 | |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma Activated T cells - Recurrent Glioblastoma | Phase 1 | Withdrawn | Jeremy Rudnick, M.D | 2026-06-01 | 2025-10-22 | |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Essential Amino Acids and Parkinsons Disease AMS2434 (amino acids), Placebo - Parkinson Disease | Phase 1 | Withdrawn | University of Arkansas | 2026-03-09 | 2026-03-12 | |
| A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases CLBR001 + SWI019 - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Withdrawn | Calibr, a division of Scripps Research | 2026-03-01 | 2026-03-05 | |
| Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis Amniotic fluid or placental CD117 stem cells - Multiple Sclerosis, Progressive | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2026-02-01 | 2026-02-06 | |
| Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALS cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells - Amyotrophic Lateral Sclerosis | Phase 1 | Withdrawn | The Foundation for Orthopaedics and Regenerative Medicine | 2025-12-01 | 2026-10-16 | |
| Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas Control Group - Standard of care neurosurgical resection, MRF/MRI infiltration guidance for extended resection - Glioblastoma, Brain Tumor | Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2025-12-01 | 2026-07-01 | |
| Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy - Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis | Phase 1 | Withdrawn | Beijing Boren Hospital | 2025-11-06 | 2026-10-15 | |
| Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection - Malignant Central Nervous System Neoplasm | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-20 | 2025-10-22 | |
| Effect of RECK in Posterior Spinal Fusion Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail, Placebo - Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease | Phase 1 / Phase 2 | Withdrawn | University of Maryland, Baltimore | 2025-10-01 | 2025-07-31 | |
| A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease gene therapy - GBA1 Parkinson Disease | Phase 1 / Phase 2 | Withdrawn | Capsida Biotherapeutics, Inc. | 2025-08-18 | 2026-06-22 | |
| Oxaloacetate in Myasthenia Gravis Oxaloacetate, Placebo - Myasthenia Gravis | Phase 1 | Withdrawn | University of Kansas Medical Center | 2025-08-01 | 2025-07-11 | |
| A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases LCAR-AIO T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) | Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-17 | 2026-06-24 | |
| Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia CYR-064 - Hyposmia, Anosmia | Phase 1 | Withdrawn | University of Nebraska | 2025-04-01 | 2025-03-13 | |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia ASP2016, Prednisolone - Friedreich Ataxia, Cardiomyopathy | Phase 1 | Withdrawn | Astellas Gene Therapies | 2024-11-08 | 2025-11-28 |
Showing 20 of 226. Sign in to see all of them.
Brain Neoplasms (31) · Stroke (20) · Parkinson Disease (16) · Central Nervous System Neoplasms (12) · Ischemic Stroke (12) · Alzheimer Disease (10) · Glioblastoma (10) · Breast Neoplasms (8) · Glioma (8) · Multiple Sclerosis (8) · Amyotrophic Lateral Sclerosis (7) · Brain Injuries, Traumatic (7) · Astrocytoma (5) · Brain Diseases (5) · Medulloblastoma (5)
Central Nervous System Diseases (146) · Brain Diseases (131) · Pathological Conditions, Signs and Symptoms (59) · Neoplasms by Site (51) · Neoplasms (49) · Nervous System Neoplasms (45) · Neurodegenerative Diseases (44) · Cardiovascular Diseases (41) · Vascular Diseases (41) · Cerebrovascular Disorders (38) · Signs and Symptoms (36) · Neurologic Manifestations (33) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (32) · Genetic Diseases, Inborn (32)
Sodium Chloride (8) · Saline Solution (5) · Dexamethasone (3) · Donepezil (3) · Specimen Handling (3) · Temozolomide (3) · pembrolizumab (3) · Aspirin (2) · Azacitidine (2) · Bevacizumab (2) · Carboplatin (2) · Dexmedetomidine (2) · GC 1 compound (2) · Ipilimumab (2) · Lidocaine (2)
Neurogen Brain and Spine Institute (13) · M.D. Anderson Cancer Center (6) · GlaxoSmithKline (5) · National Cancer Institute (NCI) (5) · University of California, San Diego (5) · Johns Hopkins University (4) · Hadassah Medical Organization (3) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Stanford University (3) · University of California, Irvine (3) · Washington University School of Medicine (3) · Ageless Regenerative Institute (2) · Aryn Knight (2) · Biogen (2) · Brigham and Women's Hospital (2)
United States (103) · India (13) · Canada (11) · Israel (6) · United Kingdom (6) · China (5) · France (3) · Germany (3) · Australia (2) · Honduras (2) · Iran (2) · Taiwan (2) · Argentina (1) · Belgium (1) · Brazil (1)
Alok K Sharma, M.S., M.Ch (4) · Matt B Jensen, MD (4) · Glenn C Terry, MD (2) · James E. Baumgartner, MD (2) · Alexandra L Goodyear, MD, MS (1) · Ali Reza Zali, MD (1) · Amar Gajjar, MD (1) · Amy L Bredlau, MD (1) · Andrew Baker, MD (1) · Andrew D Krystal, MD, MS (1) · Anli Liu, MD (1)
PMID 19425468, PMID 25126443, PMID 25164919, PMID 25500317, PMID 26381856, PMID 27910097, PMID 29386049, PMID 29765218, PMID 30152015, PMID 30232673, PMID 30617735, PMID 33175411, PMID 33203645, PMID 40739200, PMID 8615453, PMID 9364715, PMID 9840607
2023 (2), 2016 (1), 2018 (1), 2019 (1), I21RX004417 (1), K08MH094441 (1), P30CA015704 (1), P30CA022453 (1), P30CA033572 (1), P30CA060553 (1), P30CA138292 (1), P30DK034989 (1), P50NS044148 (1), UM1CA154967 (1), UM1CA186704 (1)